4.6 Article

Implications of liver injury in risk-stratification and management of patients with COVID-19

Journal

HEPATOLOGY INTERNATIONAL
Volume 15, Issue 1, Pages 202-212

Publisher

SPRINGER
DOI: 10.1007/s12072-020-10123-0

Keywords

Fatty liver disease; Viral hepatitis; Cirrhosis; Hospitalization; Disease progression; Prognosis; ICU admission; scRNA-seq analysis; TMPRSS2; Clinical prediction model

Funding

  1. National Natural Science Foundation of China [81971495, 81571564, 91442117, 81572893, 81972358, 91959113]
  2. CAMS Innovation Fund for Medical Sciences [2019-I2M-5-035]
  3. National Science Foundation of Jiangsu Province [BRA2017533, BK20191490, BE2016766]
  4. 863 Young Scientists Special Fund [SS2015AA0209322]
  5. Foundation of Jiangsu Collaborative Innovation Center of Biomedical Functional Materials, Key Foundation of Wuhan Huoshenshan Hospital [2020[18]]
  6. Key Research& Development Program of Jiangsu Province [BE2017733, BE2018713]
  7. Medical Innovation Project of Logistics Service [18JS005]
  8. Basic Research Program of Jiangsu Province [BK20180036]

Ask authors/readers for more resources

Liver injury in COVID-19 patients, especially in cases of fatty liver disease and cirrhosis, is significantly associated with disease severity and mortality. A risk-score model has been developed to predict the occurrence and severity of liver injury during hospitalizations for COVID-19 patients.
Background Infection with SARS-CoV-2 has been associated with liver dysfunction, aggravation of liver burden, and liver injury. This study aimed to assess the effects of liver injuries on the clinical outcomes of patients with COVID-19. Methods A total of 1520 patients with severe or critical COVID-19 from Huoshenshan Hospital, Wuhan, were enrolled. Chronic liver disease (CLD) was confirmed by consensus diagnostic criteria. Laboratory test results were compared between different groups. scRNA-seq data and bulk gene expression profiles were used to identify cell types associated with liver injury. Results A total of 10.98% of patients with severe or critical COVID-19 developed liver injury after admission that was associated with significantly higher rates of mortality (21.74%, p < 0.001) and intensive care unit admission (26.71%, p < 0.001). Pre-existing CLDs were not associated with a higher risk. However, fatty liver disease and cirrhosis were associated with higher risks, supported by evidences from single cell and bulk transcriptome analysis that showed more TMPRSS2(+) cells in these tissues. By generating a model, we were able to predict the risk and severity of liver injury during hospitalization. Conclusion We demonstrate that liver injury occurring during therapy as well as pre-existing CLDs like fatty liver disease and cirrhosis in patients with COVID-19 is significantly associated with the severity of disease and mortality, but the presence of other CLD is not associated. We provide a risk-score model that can predict whether patients with COVID-19 will develop liver injury or proceed to higher-risk stages during subsequent hospitalizations.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available